Insider Selling: ICU Medical, Inc. (NASDAQ:ICUI) COO Sells 1,962 Shares of Stock

ICU Medical, Inc. (NASDAQ:ICUI) COO Christian B. Voigtlander sold 1,962 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $169.08, for a total transaction of $331,734.96. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Christian B. Voigtlander also recently made the following trade(s):

• On Wednesday, November 27th, Christian B. Voigtlander sold 1,430 shares of ICU Medical stock. The shares were sold at an average price of $158.00, for a total transaction of $225,940.00.

ICU Medical Trading Up 1.3 %

NASDAQ ICUI opened at $159.75 on Friday. The company’s fifty day moving average price is $175.28 and its two-hundred day moving average price is $146.60. The company has a market capitalization of $3.91 billion, a price-to-earnings ratio of -34.96 and a beta of 0.66. ICU Medical, Inc. has a 12 month low of $83.26 and a 12 month high of $196.26. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03.

Hedge Funds Weigh In On ICU Medical

A number of hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC grew its position in shares of ICU Medical by 441.7% in the 2nd quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock worth $691,000 after acquiring an additional 4,744 shares in the last quarter. LMR Partners LLP acquired a new position in ICU Medical in the third quarter worth $3,884,000. Vanguard Group Inc. increased its stake in ICU Medical by 0.5% during the first quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after purchasing an additional 11,991 shares during the last quarter. Savant Capital LLC acquired a new stake in shares of ICU Medical during the second quarter worth $431,000. Finally, Boston Partners bought a new position in shares of ICU Medical in the 1st quarter worth about $790,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ICUI shares. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp upped their price target on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Jefferies Financial Group initiated coverage on shares of ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 price objective on the stock. Raymond James lifted their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research note on Thursday, September 12th. Finally, StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.